کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2082275 | 1080276 | 2008 | 9 صفحه PDF | دانلود رایگان |

Drug addiction can be defined by a compulsion to seek and take drug and the loss of control in limiting intake, and the excessive drug-taking derives from multiple motivational mechanisms. One such mechanism is the emergence of a negative emotional state when access to the drug is prevented, reflecting hedonic homeostatic dysregulation. Excessive drug-taking then results in part via the construct of negative reinforcement. The negative emotional state that drives such negative reinforcement is hypothesized to derive from the dysregulation of key neurochemical elements involved in reward and stress within basal forebrain structures, including the ventral striatum and extended amygdala. Specific neurochemical elements in these structures include not only decreases in reward neurotransmission, such as decreases in dopamine and opioid peptide function in the ventral striatum, but also the recruitment of brain stress systems, such as corticotropin-releasing factor (CRF), in the extended amygdala. Chronic exposure or extended access to self-administration of all the major drugs of abuse produced during abstinence increases in reward thresholds, increases in aversive anxiety-like responses, increases in extracellular levels of CRF in the central nucleus of the amygdala, and increases in drug self-administration. CRF receptor antagonists block excessive drug intake produced by dependence. A combination of decreased reward system function and increased brain stress response system function is hypothesized to be responsible for hedonic homeostatic dysregulation that drives drug-seeking behavior in dependence. Such hedonic dysregulation is hypothesized to extend into protracted abstinence to provide a residual negative emotional state that enhances the salience of cues eliciting drug seeking and relapse.
Section editors:Nigel Maidment and Niall Murphy – Hatos Center for Neuropharmacology, UCLA, Los Angeles, CA, USAM. Foster Olive – Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC, USA
Journal: Drug Discovery Today: Disease Models - Volume 5, Issue 4, Winter 2008, Pages 207–215